NCT03317912

Brief Summary

The aim of this clinical trial is to study the effect of an intravenous infusion of lidocaïne in a multimodal analgesic protocol on the architecture sleep during the first postoperative night.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Dec 2017

Shorter than P25 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2015

Completed
2.6 years until next milestone

First Posted

Study publicly available on registry

October 23, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

October 23, 2017

Status Verified

October 1, 2017

Enrollment Period

1 year

First QC Date

March 31, 2015

Last Update Submit

October 17, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time ratio between rapid eye movement sleep(REM) + Stage 3 sleep / Stage 1 + Stage 2 sleep

    Postoperaty day 1

Secondary Outcomes (4)

  • Sleep latence

    Postoperaty day 1

  • Sleep time

    Postoperaty day 1

  • Cumulative Opioid use

    Postoperaty day 1

  • Quality of analgesia (Visual Analogic Scale)

    Postoperaty day 1

Study Arms (2)

Lidocaïne 2%

ACTIVE COMPARATOR

Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h

Drug: Lidocaïne 2%

Placebo (for Lidocaïne)

PLACEBO COMPARATOR

Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h

Drug: Placebo (for Lidocaïne)

Interventions

Continuous infusion during per and postoperative periods

Also known as: lignocaïne, Linisol
Lidocaïne 2%

Continuous infusion during per and postoperative periods

Also known as: NaCl 0.9%
Placebo (for Lidocaïne)

Eligibility Criteria

Age18 Years - 65 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Radical prostatectomy

You may not qualify if:

  • BMI \> 30
  • Neurologic/psychiatric diseases or therapeutics, seizyres
  • Cardiac disease, second or third degree atrioventricular block
  • Obstructive sleep apnea syndrome
  • History of liver or renal insufficiency
  • and any contraindication to the anesthetic protocol of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6. doi: 10.1097/00000542-200701000-00007.

  • Krenk L, Jennum P, Kehlet H. Postoperative sleep disturbances after zolpidem treatment in fast-track hip and knee replacement. J Clin Sleep Med. 2014 Mar 15;10(3):321-6. doi: 10.5664/jcsm.3540.

MeSH Terms

Conditions

Parasomnias

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Sleep Wake DisordersNervous System DiseasesMental Disorders

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Isabelle Maquoi

    CHU Liege - Department of Anesthesia and Intensive Care Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Isabelle Maquoi

CONTACT

Gregory Hans

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 31, 2015

First Posted

October 23, 2017

Study Start

December 1, 2017

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

October 23, 2017

Record last verified: 2017-10